Related Experiment Video

Updated: Jun 17, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Denosumab: the era of targeted therapies in bone metastatic diseases

D Santini1, M E Fratto, B Vincenzi

  • 1Medical Oncology, University Campus Bio-Medico, Rome, Italy.

Current Cancer Drug Targets
|December 23, 2009
PubMed

Insights

Denosumab, a RANKL inhibitor, shows promise in preventing bone loss and skeletal events in cancer patients. Ongoing studies explore its role in preventing disease recurrence in solid tumors, advancing bone health care.

Area of Science:

  • Oncology
  • Bone Metabolism
  • Pharmacology

Background:

  • The RANKL/RANK/OPG system is crucial for bone resorption.
  • Denosumab is a monoclonal antibody targeting RANKL.
  • Cancer treatments can negatively impact bone health.

Purpose of the Study:

  • To review clinical trial data on denosumab in medical oncology.
  • To discuss denosumab's efficacy in preventing cancer treatment-induced bone loss (CTIBL).
  • To evaluate denosumab's role in preventing skeletal-related events (SREs) and disease recurrence.

Main Methods:

  • Systematic review of clinical trial results.
  • Analysis of data on denosumab's impact on bone health in cancer patients.
  • Inclusion of studies on CTIBL, SREs, and adjuvant settings.

Main Results:

  • Denosumab demonstrates potential in preventing CTIBL.
  • Evidence suggests denosumab reduces SREs in bone metastatic patients.
  • Ongoing trials investigate denosumab for disease recurrence prevention.

Conclusions:

  • Denosumab is a significant therapeutic option for managing bone complications in cancer patients.
  • Further research is warranted to fully elucidate denosumab's benefits in oncology.
  • Clinical data supports denosumab's role in improving bone health outcomes for cancer survivors.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...